Clinical Trial Update: A Study to Evaluate the Pharmacodynamic (PD) Effects of Once Weekly Administration of Gantenerumab in Participants With Early Alzheimer's Disease (AD) [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pharmacodynamic effects of once-weekly gantenerumab in early Alzheimer's disease was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Gantenerumab (gantenerumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Alzheimer Disease | Phase 2 | Status: TERMINATED | Results posted: 2024-03-27